RxDoctor Payments Data

Afshan Hameeduddin, MD

Family Medicine · Schaumburg, ILNPI 1992884084

Payments from drug & device makers

$6,738in general payments, 2019–2025

Across 364 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$888
  • Pfizer$599
  • AstraZeneca$356
  • GSK$348
  • E.r. Squibb & Sons, L.L.C.$345
  • Bayer$332
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$6,63899%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,738 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$436,695
Medicare patients
793
Services billed
4,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,038$366,483
JardianceEmpagliflozin366$172,859
JanuviaSitagliptin Phosphate219$115,935
ProliaDenosumab36$67,153
XareltoRivaroxaban165$58,595
OzempicSemaglutide55$54,054
LinzessLinaclotide85$49,439
TradjentaLinagliptin85$40,848
TrulicityDulaglutide41$40,779
MyrbetriqMirabegron96$38,632
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$29,463
Breo ElliptaFluticasone/Vilanterol59$27,989
Potassium Chloride702$27,509
RybelsusSemaglutide21$27,227
EntrestoSacubitril/Valsartan60$24,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$599$366,4831,038 claims
Boehringer IngelheimJardiance, Tradjenta$206$213,707451 claims
MerckJanuvia, Lagevrio (Eua)$78$126,957232 claims
Novo NordiskOzempic, Rybelsus$182$81,28176 claims
AmgenProlia$260$67,15336 claims
AbbVieLinzess, Restasis$888$59,137110 claims
Johnson & JohnsonXarelto$132$58,595165 claims
Lilly USA, LLCTrulicity, Mounjaro$283$58,43759 claims
GSKTrelegy Ellipta, Breo Ellipta$348$57,453102 claims
AstraZenecaLokelma, Farxiga$356$45,92688 claims
Astellas Pharma US IncMyrbetriq$228$38,63296 claims
NovartisEntresto$274$24,18460 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Schaumburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →